Antiplatelet therapy after coronary intervention in Asia and Japan

Summary

Currently available clinical database was mostly developed in North America and Europe (Western Countries). Clinical database of Asian patients are still not large enough to develop Asian region specific clinical guidelines, although the population of patients in the majority of Asia countries are increasing rapidly. Marked ethnic and life-style heterogeneity within Asian region also makes it difficult to develop Asian region specific Evidence-based clinical practice guidelines. In general, there are certain differences in the background epidemiology of the athero-sclerotic and thrombotic diseases in Asia countries and Western ones such as Asian patients are more prone to cerebrovascular disease (CVD) than coronary artery disease (CAD). Accordingly, there also are marked differences in the use of antiplatelet agents in Asian patients underwent coronary intervention (such as frequent use of cilostazol) as compared to those living in the Western countries. Currently available database also suggests the difference in side effects of anti -platelet agents in Asian patients as compared to Western ones such as relatively high incidence of hepatic dysfunction with the use of thienopiridine. In the future, it would be important to clarify the detailed difference of Asian patients and Western ones in regards to the effects and side effects of antiplatelet therapy by the multi-national prospective observation registry and clinical trials including equal number of Asian and Western patients. It would also be important for Asian physician to develop scientifically valid methods to import the results of “Global Evidence” with appropriate modification for the clinical practice in patients living in the specific region of Asia.

Keywords

Antiplatelet agents - Asia - Japan - aspirin - ticlopidine - clopidogrel - atrial fibrillation - intracranial bleeding

• References

• 1 Bhatt DL, Steg PG, Ohman EM. et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006; 295: 180-189.
• 2 Goto S. Cardiovascular risk factors in patients at high risk of atherothrombosis: what can be learned from registries?. Thromb Haemost 2008; 100: 611-613.
• 3 Kiyohara Y, Kubo M, Kato I. et al. Ten-year prognosis of stroke and risk factors for death in a Japanese community: the Hisayama study. Stroke 2003; 34: 2343-2347.
• 4 Kubo M, Kiyohara Y, Kato I. et al. Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: the Hisayama study. Stroke 2003; 34: 2349-2354.
• 5 Steg PG, Bhatt DL, Wilson PW. et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 2007; 297: 1197-1206.
• 6 Ueda K, Hasuo Y, Kiyohara Y. et al. Intracerebral hemorrhage in a Japanese community, Hisayama: incidence, changing pattern during long-term follow-up, and related factors. Stroke 1988; 19: 48-52.
• 7 Ueda K, Omae T, Hasuo Y. et al. Prevalence and long-term prognosis of mild hypertensives and hypertensives in a Japanese community, Hisayama. J Hypertens 1988; 6: 981-989.
• 8 Wilson PW, D’Agostino RB, Levy D. et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-1847.
• 9 Worth RM, Kato H, Rhoads GG. et al. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California: mortality. Am J Epidemiol 1975; 102: 481-490.
• 10 Yamazaki T, Goto S, Shigematsu H. et al. Prevalence, awareness and treatment of cardiovascular risk factors in patients at high risk of atherothrombosis in Japan. Circ J 2007; 71: 995-1003.
• 11 Shen AY, Yao JF, Brar SS. et al. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol. 2007; 50: 309-315.
• 12 Ro A, Hara M, Takada A. The factor V Leiden mutation and the prothrombin G20210A mutation was not found in Japanese patients with pulmonary thromboembolism. Thromb Haemost 1999; 82: 1769.
• 13 Jun ZJ, Ping T, Lei Y. et al. Prevalence of factor V Leiden and prothrombin G20210A mutations in Chinese patients with deep venous thrombosis and pulmonary embolism. Clin Lab Haematol 2006; 28: 111-116.
• 14 Prasmusinto D, Skrablin S, Fimmers R, van der Ven K. Ethnic differences in the association of factor V Leiden mutation and the C677T methylenetetrahydrofolate reductase gene polymorphism with preeclampsia. Eur J Obstet Gynecol Reprod Biol 2004; 112: 162-169.
• 15 Sakuma M, Konno Y, Shirato K. Increasing mortality from pulmonary embolism in Japan, 1951–2000. Circ J 2002; 66: 1144-1149.
• 16 Goto S, Tamura N, Handa S. et al. Involvement of glycoprotein VI in platelet thrombus formation on both collagen and von Willebrand factor surfaces under flow conditions. Circulation 2002; 106: 266-272.
• 17 Goto S, Tamura N, Eto K. et al. Functional significance of adenosine 5‘-diphosphate receptor (P2Y(12)) in platelet activation initiated by binding of von Willebrand factor to platelet GP Ibalpha induced by conditions of high shear rate. Circulation 2002; 105: 2531-2536.
• 18 Moriguchi-Goto S, Yamashita A, Tamura N. et al. ADAMTS-13 attenuates thrombus formation on type I collagen surface and disrupted plaques under flow conditions. Atherosclerosis 2009; 203: 409-416.
• 19 Goto S, Tamura N, Li M. et al. Different effects of various anti-GPIIb-IIIa agents on shear-induced platelet activation and expression of procoagulant activity. J Thromb Haemost 2003; 1: 2022-2030.
• 20 Hoshiba Y, Hatakeyama K, Tanabe T. et al. Co-localization of von Willebrand factor with platelet thrombi, tissue factor and platelets with fibrin, and consistent presence of inflammatory cells in coronary thrombi obtained by an aspiration device from patients with acute myocardial infarction. J Thromb Haemost 2006; 4: 114-120.
• 21 Tamura N, Kitajima I, Kawamura Y. et al. Important regulatory role of activated platelet-derived procoagulant activity in the propagation of thrombi formed under arterial blood flow conditions. Circ J 2009; 73: 540-548.
• 22 Hagihara M, Higuchi A, Tamura N. et al. Platelets, after exposure to a high shear stress, induce IL-10-producing, mature dendritic cells in vitro. J Immunol 2004; 172: 5297-5303.
• 23 Goto S. Blood constitution: platelet aggregation, bleeding, and involvement of leukocytes. Rev Neurol Dis 2008; 5 (Suppl. 01) S22-27.
• 24 Goto S. Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. Atheroscler Suppl 2005; 6: 3-11.
• 25 Shinohara Y, Gotoh F, Tohgi H. et al. Antiplatelet cilostazol is beneficial in diabetic and/or hypertensive ischemic stroke patients. Subgroup analysis of the cilostazol stroke prevention study. Cerebrovasc Dis 2008; 26: 63-70.
• 26 Huang Y, Cheng Y, Wu J. et al. Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. Lancet Neurol 2008; 7: 494-499.
• 27 Angiolillo DJ, Capranzano P, Goto S. et al. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual anti-platelet therapy: results of the OPTIMUS-2 study. Eur Heart J 2008; 29: 2202-2211.
• 28 Kawata M, Kuramoto E, Kataoka T. et al. Comparative inhibitory effects of cilostazol and ticlopi-dine on subacute stent thrombosis and platelet function in acute myocardial infarction patients with percutaneous coronary intervention. Int Heart J 2005; 46: 13-22.
• 29 Chen KY, Rha SW, Li YJ. et al. Triple versus dual anti-platelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation 2009; 119: 3207-3214.
• 30 Lee SW, Park SW, Hong MK. et al. Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis. J Am Coll Cardiol 2005; 46: 1833-1837.
• 31 Douglas Jr JS, Holmes Jr DR, Kereiakes DJ. et al. Coronary stent restenosis in patients treated with cilostazol. Circulation 2005; 112: 2826-2832.
• 32 Lee SW, Park SW, Kim YH. et al. Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial. J Am Coll Cardiol 2008; 51: 1181-1187.
• 33 Martin K, Weiss S, Metharom P. et al. Thrombin stimulates smooth muscle cell differentiation from peripheral blood mononuclear cells via Protease-Activated Receptor-1, RhoA, and myocardin. Circ Res 2009; 105: 214-218.
• 34 Fukuuchi Y, Tohgi H, Okudera T. et al. A randomized, double-blind study comparing the safety and efficacy of clopidogrel versus ticlopidine in Japanese patients with noncardioembolic cerebral infarction. Cerebrovasc Dis 2008; 25: 40-49.
• 35 Uchiyama S, Fukuuchi Y, Yamaguchi T. The safety and efficacy of clopidogrel versus ticlopidine in Japanese stroke patients: combined results of two Phase III multicenter, randomized clinical trials. J Neurol 2009; 256: 888-897.
• 36 Fuster V, Ryden LE, Asinger RW. et al. ACC/AHA/ ESC guidelines for the management of patients with atrial fibrillation. Circulation 2001; 104: 2118-2150.
• 37 Grines CL, Bonow RO, Casey Jr DE. et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents. Circulation 2007; 115: 813-818.
• 38 Goto S, Bhatt DL, Rother J. et al. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J 2008; 156: 855-863 863 e852.
• 39 Connolly SJ, Pogue J, Hart RG. et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009; 360: 2066-2078.
• 40 Toyoda K, Yasaka M, Iwade K. et al. Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease: a prospective, multicenter, observational study. Stroke 2008; 39: 1740-1745.
• 41 Berger JS, Brown DL, Becker RC. Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis. Am J Med 2008; 121: 43-49.
• 42 Asano T, Kobayashi Y, Fukushima K. et al. Safety and efficacy of low-dose clopidogrel in Japanese patients undergoing coronary stenting: preliminary 30-day clinical outcome. Circ J 2008; 72: 1707-1708.
• 43 Hollopeter G, Jantzen HM, Vincent D. et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001; 409 6817 202-207.
• 44 Hoshino K, Horiuchi H, Tada T. et al. Clopidogrel resistance in Japanese patients scheduled for percutaneous coronary intervention. Circ J 2009; 73: 336-342.